利用基于体细胞基因组编辑的小鼠肝癌模型预测免疫检查点抑制剂反应
研究通过水动力尾静脉注射转座子与CRISPR-Cas9系统建立模拟人类肝癌基因组成的小鼠肝癌模型,按肿瘤浸润CD8+ T细胞水平分为冷肿瘤与热肿瘤。抗PD-1治疗对冷肿瘤无效而对热肿瘤非常有效,索拉非尼可使冷肿瘤对 anti-PD-1 敏感。作者认为单用 anti-PD-1 可能对驱动热肿瘤的基因突变肝癌有效,而 anti-PD-1 联合索拉非尼可能更适合驱动冷肿瘤的基因突变肝癌。
要点
- 基于肿瘤浸润CD8+ T细胞水平可将不同基因型小鼠肝癌分为冷肿瘤与热肿瘤。
- 抗PD-1治疗在冷肿瘤中无效,在热肿瘤中非常有效。
- 索拉非尼使 Trp53KO/MYCOE 冷肿瘤对抗PD-1治疗敏感。
核心结论
- 单用抗PD-1治疗似乎对驱动热肿瘤的基因突变肝癌有效,而抗PD-1联合索拉非尼可能更适合驱动冷肿瘤的基因突变肝癌。
研究设计与样本
- 研究采用水动力尾静脉注射转座子与CRISPR-Cas9系统进行基因组编辑,建立基因型密切模拟人类肝癌基因组成的小鼠肝癌模型。
- 对小鼠肝癌肿瘤进行RNA测序,对肿瘤浸润T细胞进行流式细胞术与单细胞RNA测序分析。
主要发现
- 基于CD8+ T细胞浸润水平,将不同基因型肿瘤分为冷肿瘤与热肿瘤。
- 抗PD-1治疗在冷肿瘤中无效果,但在热肿瘤中非常有效。
- Keap1KO/MYCOE 肝癌的肿瘤浸润CD8+ T细胞较 Trp53KO/MYCOE 肝癌表达更高水平的促炎趋化因子,并富集祖耗竭CD8+ T细胞表型。
- 索拉非尼使 Trp53KO/MYCOE 肝癌对抗PD-1治疗敏感。
临床怎么用
- 作者认为,单用抗PD-1治疗似乎对驱动热肿瘤的基因突变肝癌有效。
- 作者认为,抗PD-1联合索拉非尼可能更适合驱动冷肿瘤的基因突变肝癌。
- 作者认为,本研究可能有助于指导涉及抗PD-1的单药或联合治疗的患者分层系统设计。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) are the only two classes of FDA-approved drugs for individuals with advanced hepatocellular carcinoma (HCC). While TKIs confer only modest survival benefits, ICIs have been associated with remarkable outcomes but only in the minority of patients who respond. Understanding the mechanisms that determine the efficacy of ICIs in HCC will help to stratify patients likely to respond to ICIs. This study aims to elucidate how genetic composition and specific oncogenic pathways regulate the immune composition of HCC, which directly affects response to ICIs. METHODS: A collection of mouse HCCs with genotypes that closely simulate the genetic composition found in human HCCs were established using genome-editing approaches involving the delivery of transposon and CRISPR-Cas9 systems by hydrodynamic tail vein injection. Mouse HCC tumors were analyzed by RNA-sequencing while tumor-infiltrating T cells were analyzed by flow cytometry and single-cell RNA-sequencing. RESULTS: Based on the CD8+ T cell-infiltration level, we characterized tumors with different genotypes into cold and hot tumors. Anti-PD-1 treatment had no effect in cold tumors but was greatly effective in hot tumors. As proof-of-concept, a cold tumor (Trp53KO/MYCOE) and a hot tumor (Keap1KO/MYCOE) were further characterized. Tumor-infiltrating CD8+ T cells from Keap1KO/MYCOE HCCs expressed higher levels of proinflammatory chemokines and exhibited enrichment of a progenitor exhausted CD8+ T-cell phenotype compared to those in Trp53KO/MYCOE HCCs. The TKI sorafenib sensitized Trp53KO/MYCOE HCCs to anti-PD-1 treatment. CONCLUSION: Single anti-PD-1 treatment appears to be effective in HCCs with genetic mutations driving hot tumors, while combined anti-PD-1 and sorafenib treatment may be more appropriate in HCCs with genetic mutations driving cold tumors. IMPACT AND IMPLICATIONS: Genetic alterations of different driver genes in mouse liver cancers are associated with tumor-infiltrating CD8+ T cells and anti-PD-1 response. Mouse HCCs with different genetic compositions can be grouped into hot and cold tumors based on the level of tumor-infiltrating CD8+ T cells. This study provides proof-of-concept evidence to show that hot tumors are responsive to anti-PD-1 treatment while cold tumors are more suitable for combined treatment with anti-PD-1 and sorafenib. Our study might help to guide the design of patient stratification systems for single or combined treatments involving anti-PD-1.
引用
- Yuen VW, Chiu DK, Law CT, et al. Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses. J Hepatol. 2022. PMID: 36455783. doi:10.1016/j.jhep.2022.10.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。